TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.


Options:
A: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
B: Arm Label: Sitagliptin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: sitagliptin (MK0431) | Arm Label: Glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: glipizide | Intervention Type: DRUG; Name: sitagliptin (MK0431); Assigned to Arm(s): Sitagliptin 100 mg | Intervention Type: DRUG; Name: Comparator: glipizide; Assigned to Arm(s): Glipizide
C: Arm Label: linagliptin; Type: EXPERIMENTAL; Interventions: Drug: linagliptin, Drug: glimepiride placebo | Arm Label: glimepiride 1-4 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: linagliptin placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): glimepiride 1-4 mg QD | Intervention Type: DRUG; Name: linagliptin placebo; Assigned to Arm(s): glimepiride 1-4 mg QD | Intervention Type: DRUG; Name: glimepiride placebo; Assigned to Arm(s): linagliptin
D: Arm Label: Lira 0.6 + Met; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: metformin, Drug: placebo | Arm Label: Lira 1.2 + Met; Type: EXPERIMENTAL; Interventions: Drug: metformin, Drug: placebo, Drug: liraglutide | Arm Label: Lira 1.8 + Met; Type: EXPERIMENTAL; Interventions: Drug: metformin, Drug: placebo, Drug: liraglutide | Arm Label: Met Mono; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin, Drug: placebo | Arm Label: Met + Glim; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin, Drug: glimepiride, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 0.6 + Met | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met, Met + Glim, Met Mono | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Met + Glim | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 0.6 + Met, Lira 1.2 + Met, Lira 1.8 + Met, Met Mono | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Met + Glim, Met Mono | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 + Met | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 + Met

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.


Options:
A: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Exenatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: exenatide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: exenatide; Assigned to Arm(s): Exenatide
C: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes
Brief Summary: This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.


Options:
A: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
C: Arm Label: Lira 1.8; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Lira 1.2; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Glimepiride - 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: placebo | Arm Label: Glimepiride - 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Glimepiride - 1, Glimepiride - 2 | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 1.2, Lira 1.8 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glimepiride - 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glimepiride - 2
D: Arm Label: Exenatide Once Weekly; Type: EXPERIMENTAL; Interventions: Drug: exenatide, long acting release | Arm Label: Exenatide Twice Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: exenatide | Intervention Type: DRUG; Name: exenatide, long acting release; Assigned to Arm(s): Exenatide Once Weekly | Intervention Type: DRUG; Name: exenatide; Assigned to Arm(s): Exenatide Twice Daily

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Vocational Rehabilitation on Mentally III Veterans
Brief Summary: To study the impact of Individual Placement and Support (IPS) supported employment (SE) compared to treatment-as-usual vocational rehabilitation program (VRP) for veterans with posttraumatic stress disorder (PTSD).


Options:
A: Arm Label: Cognitive Training; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Training | Arm Label: Standard Pharmacotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Training; Assigned to Arm(s): Cognitive Training
B: Arm Label: Functional remediation; Type: EXPERIMENTAL; Interventions: Behavioral: Functional remediation | Arm Label: Psychoeducation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoeducation | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Functional remediation; Assigned to Arm(s): Functional remediation | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Assigned to Arm(s): Psychoeducation | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as Usual
C: Arm Label: Vocational Rehabilitation Program (VRP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Vocational Rehabilitation Program (VRP) | Arm Label: Individual Placement and Support (IPS); Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support (IPS) | Intervention Type: BEHAVIORAL; Name: Vocational Rehabilitation Program (VRP); Assigned to Arm(s): Vocational Rehabilitation Program (VRP) | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support (IPS); Assigned to Arm(s): Individual Placement and Support (IPS)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive enhancement therapy (CET) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Enriched supportive therapy (EST) | Intervention Type: BEHAVIORAL; Name: Cognitive enhancement therapy (CET); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enriched supportive therapy (EST); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.


Options:
A: Arm Label: sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: FAI insert; Type: EXPERIMENTAL; Interventions: Drug: FAI insert | Intervention Type: DRUG; Name: FAI insert; Assigned to Arm(s): FAI insert | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): sham injection
B: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care
C: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): 3
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2
C: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care
D: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.


Options:
A: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care
B: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg
C: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Dilated Cardiomyopathy
Brief Summary: The purpose of this study is to determine effect of cell therapy in patients with severe dilated cardiomyopathy


Options:
A: Arm Label: Auto-hMSCs; Type: EXPERIMENTAL; Interventions: Biological: Auto-hMSCs | Arm Label: Allo-hMSCs; Type: EXPERIMENTAL; Interventions: Biological: Allo-hMSCs | Intervention Type: BIOLOGICAL; Name: Auto-hMSCs; Assigned to Arm(s): Auto-hMSCs | Intervention Type: BIOLOGICAL; Name: Allo-hMSCs; Assigned to Arm(s): Allo-hMSCs
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous human mesenchymal cells (hMSCs) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous human bone marrow cells (hBMCs) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Autologous human mesenchymal cells (hMSCs); Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Autologous human bone marrow cells (hBMCs); Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 3
C: Arm Label: Autologous hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Autologous hMSCs | Arm Label: Allogeneic hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Allogeneic hMSCs | Intervention Type: BIOLOGICAL; Name: Autologous hMSCs; Assigned to Arm(s): Autologous hMSCs | Intervention Type: BIOLOGICAL; Name: Allogeneic hMSCs; Assigned to Arm(s): Allogeneic hMSCs
D: Arm Label: Optimal Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: optimal therapy for cardiaca failure | Arm Label: cell therapy; Type: EXPERIMENTAL; Interventions: Procedure: cell | Intervention Type: DRUG; Name: optimal therapy for cardiaca failure; Assigned to Arm(s): Optimal Therapy | Intervention Type: PROCEDURE; Name: cell; Assigned to Arm(s): cell therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm) to Improve Glycemic Control Through Behavioral and Therapeutic Changes
Brief Summary: Insulin therapy requires monitoring and frequent review of glucose levels to optimize dosing. Effective presentation and data analysis are essential. We examined HbA1c changes using the OneTouch(R) UltraSmart(R) System (Test Group), an integrated glucose meter and electronic logbook, compared to established meters with paper logbooks (Control Group).


Options:
A: Intervention Type: DEVICE; Name: OneTouch(r) UltraSmart(r); Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: In Home Health Messaging Device | Intervention Type: BEHAVIORAL; Name: In Home Health Messaging Device; Assigned to Arm(s): Arm 1
C: Intervention Type: BEHAVIORAL; Name: Internet co-management module; Assigned to Arm(s): N/A
D: Arm Label: Telemedicine case management; Type: EXPERIMENTAL; Interventions: Device: Telemedicine Unit (HTU) | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: DEVICE; Name: Telemedicine Unit (HTU); Assigned to Arm(s): Telemedicine case management | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Usual care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.
Brief Summary: This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.


Options:
A: Arm Label: All Enrolled Participants; Type: N/A; Interventions: Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s) | Intervention Type: DRUG; Name: Standard of care for treatment of osteoarthritis (OA) of knee(s); Assigned to Arm(s): All Enrolled Participants
B: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.
Brief Summary: This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
B: Arm Label: Saizen®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Saizen® | Arm Label: Placebo + Saizen®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo and Saizen® | Intervention Type: DRUG; Name: Saizen®; Assigned to Arm(s): Saizen® | Intervention Type: DRUG; Name: Placebo and Saizen®; Assigned to Arm(s): Placebo + Saizen®
C: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: Melatonin and Placebo; Type: EXPERIMENTAL; Interventions: Drug: Melatonin and Placebo | Arm Label: Amitriptyline and placebo; Type: EXPERIMENTAL; Interventions: Drug: Amitriptyline and Placebo | Arm Label: Melatonin and Amitriptylin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melatonin and Amitriptylin | Intervention Type: DRUG; Name: Melatonin and Placebo; Assigned to Arm(s): Melatonin and Placebo | Intervention Type: DRUG; Name: Amitriptyline and Placebo; Assigned to Arm(s): Amitriptyline and placebo | Intervention Type: DRUG; Name: Melatonin and Amitriptylin; Assigned to Arm(s): Melatonin and Amitriptylin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 14 Week, Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin Twice Daily In Patients With Fibromyalgia.
Brief Summary: This study, will compare pregabalin with placebo for the duration of 14 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
C: Intervention Type: DRUG; Name: NGX-4010; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Capsaicin Dermal Patch; Assigned to Arm(s): N/A

Answer: B